Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers | Zendy

Rodrigo E. Mendes | Zendy; Mariana Castanheira | Zendy; Leah N. Woosley | Zendy; Gregory G. Stone | Zendy; Patricia A. Bradford | Zendy; Robert K. Flamm | Zendy

Open Access

Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers

Author(s) -

Rodrigo E. Mendes,

Mariana Castanheira,

Leah N. Woosley,

Gregory G. Stone,

Patricia A. Bradford,

Robert K. Flamm

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02655-18

Subject(s) - ceftazidime/avibactam , ceftazidime , microbiology and biotechnology , biology , pathogen , avibactam , bacteria , pseudomonas aeruginosa , genetics

REPRISE was a pathogen-directed (ceftazidime-resistant) phase 3 prospective, open-label, randomized, multicenter trial that evaluated the efficacy, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) and best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). This study characterized the β-lactamase content of ceftazidime-resistantEnterobacteriaceae andPseudomonas aeruginosa recovered during the baseline visits of patients enrolled in REPRISE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research